{"id":47998,"date":"2022-09-06T14:01:42","date_gmt":"2022-09-06T12:01:42","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/maia-biotechnology-to-present-design-of-thio-101-trial-at-european-society-for-medical-oncology-esmo-congress-2022\/"},"modified":"2022-09-06T14:01:42","modified_gmt":"2022-09-06T12:01:42","slug":"maia-biotechnology-to-present-design-of-thio-101-trial-at-european-society-for-medical-oncology-esmo-congress-2022","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/maia-biotechnology-to-present-design-of-thio-101-trial-at-european-society-for-medical-oncology-esmo-congress-2022\/","title":{"rendered":"MAIA Biotechnology to Present Design of THIO-101 Trial at European Society for Medical Oncology (ESMO) Congress 2022"},"content":{"rendered":"<div>\n<p class=\"bwalignc\">\n<i>Multicenter, open-label, dose-finding trial evaluating THIO sequenced with cemiplimab in patients with advanced non-small cell lung cancer<\/i>\n<\/p>\n<p>CHICAGO&#8211;(BUSINESS WIRE)&#8211;MAIA Biotechnology, Inc. (NYSE American: MAIA) (\u201cMAIA,\u201d \u201cthe Company\u201d), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it will present the design of its ongoing THIO-101 trial at the European Society for Medical Oncology (ESMO) Congress 2022, being held from September 9<sup>th<\/sup> to 13<sup>th<\/sup> in Paris, France.\n<\/p>\n<p>\nTHIO is a telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). The first patient was enrolled in the THIO-101 study in July 2022 in Australia.\n<\/p>\n<p>\nDetails of the presentation are as follows:\n<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<b>Abstract title:<\/b> A Phase 2, Multicenter, Open-Label, Dose-Finding Study Evaluating THIO Sequenced with Cemiplimab in Patients with Advanced NSCLC \u2013 A Trial in Progress\n<\/li>\n<li>\n<b>Abstract number:<\/b> 1193\n<\/li>\n<li>\n<b>Session title: <\/b>Trial in Progress (TiP)\n<\/li>\n<li>\n<b>Presentation date: <\/b>Monday, September 12\n<\/li>\n<\/ul>\n<p>\nThe full abstract is available on the <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.esmo.org%2Fmeetings%2Fesmo-congress-2022&amp;esheet=52857912&amp;newsitemid=20220905005459&amp;lan=en-US&amp;anchor=ESMO+Congress+2022+website&amp;index=1&amp;md5=b45342d79fcc2f8fc651639216f96e00\" rel=\"nofollow noopener\" shape=\"rect\">ESMO Congress 2022 website<\/a>.\n<\/p>\n<p>\n<b>About THIO<\/b>\n<\/p>\n<p>\nTHIO (6-thio-dG or 6-thio-2\u2019-deoxyguanosine) is a telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC), in sequential administration with cemiplimab (Libtayo<span>\u00ae<\/span>), a PD-1 inhibitor developed by Regeneron. Telomeres play a fundamental role in the survival of cancer cells and their resistance to current therapies. THIO is being developed as a second or higher line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.\n<\/p>\n<p>\n<b>About MAIA Biotechnology, Inc.<\/b>\n<\/p>\n<p>\nMAIA is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. The Company\u2019s lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of patients with telomerase-positive cancers. For more information, please visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.maiabiotech.com&amp;esheet=52857912&amp;newsitemid=20220905005459&amp;lan=en-US&amp;anchor=www.maiabiotech.com&amp;index=2&amp;md5=9a7d51717acc321dab7cab0a1b162d2b\" rel=\"nofollow noopener\" shape=\"rect\">www.maiabiotech.com<\/a>.\n<\/p>\n<p>\n<b>Forward Looking Statements<\/b>\n<\/p>\n<p>\nThis press release includes forward-looking statements including, but not limited to, statements related to the closing of the offering and the expected use of proceeds, development of drug candidates, our operations and business strategy, our expected financial results, and corporate updates. The forward-looking statements contained in this press release are based on management\u2019s current expectations and are subject to substantial risks, uncertainty and changes in circumstances. Actual results may differ materially from those expressed by these expectations due to risks and uncertainties, including, among others, those related to our ability to obtain additional capital on favorable terms to us, or at all, including, without limitation, to fund our current and future preclinical studies and clinical trials and the success, timing and cost of our drug development program and our ongoing or future preclinical studies and clinical trials, including, without limitation, the possibility of unfavorable new clinical and preclinical data and additional analyses of existing data, that the risks that prior clinical and preclinical results may not be replicated, and risks associated with the current coronavirus pandemic. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to review or update any forward-looking statement except as may be required by applicable law.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\nI<b>nvestor Inquiries<\/b>\n<\/p>\n<p>\nMAIA Biotechnology<br \/>\n<br \/>Joseph McGuire<br \/>\n<br \/>Chief Financial Officer<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#x6c;&#x74;&#x6f;&#x3a;&#x6a;&#x6d;&#x63;&#x67;&#117;&#105;&#114;&#101;&#64;&#109;&#97;iabiot&#x65;&#x63;&#x68;&#x2e;&#x63;&#x6f;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#106;m&#x63;g&#x75;i&#x72;e&#x40;&#109;&#x61;&#105;&#x61;&#98;&#x69;&#111;t&#101;c&#x68;&#46;&#x63;o&#x6d;<\/a><br \/>904-228-2603\n<\/p>\n<p>\nICR Westwicke<br \/>\n<br \/>Stephanie Carrington<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#108;&#116;&#111;:S&#x74;&#x65;&#x70;&#x68;&#97;&#110;ie&#x2e;&#x63;&#x61;&#x72;&#114;&#105;ng&#x74;&#x6f;&#x6e;&#x40;&#119;&#101;&#115;tw&#x69;&#x63;&#x6b;&#x65;&#46;&#99;om\" rel=\"nofollow noopener\" shape=\"rect\">&#83;&#x74;e&#x70;&#x68;&#97;&#x6e;i&#101;&#x2e;&#99;&#x61;r&#114;&#x69;n&#x67;t&#111;&#x6e;&#64;&#x77;&#x65;&#115;&#x74;w&#105;&#x63;&#107;&#x65;&#46;&#99;&#x6f;&#109;<\/a><br \/>646-277-1282\n<\/p>\n<p>\n<b>Media Inquiries<\/b>\n<\/p>\n<p>\nICR Westwicke<br \/>\n<br \/>Sean Leous<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#105;&#108;to&#x3a;&#x53;&#x65;&#97;n&#46;&#x6c;&#x65;&#x6f;&#117;&#115;&#64;&#x77;&#x65;&#x73;&#116;&#119;i&#x63;&#x6b;&#x65;&#46;&#99;om\" rel=\"nofollow noopener\" shape=\"rect\">&#83;e&#x61;n&#x2e;l&#x65;&#111;&#x75;&#115;&#x40;&#119;e&#x73;t&#x77;i&#x63;&#107;&#x65;&#46;&#x63;&#111;&#x6d;<\/a><br \/>646-866-4012\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Multicenter, open-label, dose-finding trial evaluating THIO sequenced with cemiplimab in patients with advanced non-small cell lung cancer CHICAGO&#8211;(BUSINESS WIRE)&#8211;MAIA Biotechnology, Inc. (NYSE American: MAIA) (\u201cMAIA,\u201d \u201cthe Company\u201d), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it will present the design of its ongoing THIO-101 trial at the European Society for Medical &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/maia-biotechnology-to-present-design-of-thio-101-trial-at-european-society-for-medical-oncology-esmo-congress-2022\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-47998","format-standard","category-industry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MAIA Biotechnology to Present Design of THIO-101 Trial at European Society for Medical Oncology (ESMO) Congress 2022 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/maia-biotechnology-to-present-design-of-thio-101-trial-at-european-society-for-medical-oncology-esmo-congress-2022\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MAIA Biotechnology to Present Design of THIO-101 Trial at European Society for Medical Oncology (ESMO) Congress 2022 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Multicenter, open-label, dose-finding trial evaluating THIO sequenced with cemiplimab in patients with advanced non-small cell lung cancer CHICAGO&#8211;(BUSINESS WIRE)&#8211;MAIA Biotechnology, Inc. (NYSE American: MAIA) (\u201cMAIA,\u201d \u201cthe Company\u201d), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it will present the design of its ongoing THIO-101 trial at the European Society for Medical ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/maia-biotechnology-to-present-design-of-thio-101-trial-at-european-society-for-medical-oncology-esmo-congress-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-09-06T12:01:42+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maia-biotechnology-to-present-design-of-thio-101-trial-at-european-society-for-medical-oncology-esmo-congress-2022\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maia-biotechnology-to-present-design-of-thio-101-trial-at-european-society-for-medical-oncology-esmo-congress-2022\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"MAIA Biotechnology to Present Design of THIO-101 Trial at European Society for Medical Oncology (ESMO) Congress 2022\",\"datePublished\":\"2022-09-06T12:01:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maia-biotechnology-to-present-design-of-thio-101-trial-at-european-society-for-medical-oncology-esmo-congress-2022\\\/\"},\"wordCount\":547,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maia-biotechnology-to-present-design-of-thio-101-trial-at-european-society-for-medical-oncology-esmo-congress-2022\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maia-biotechnology-to-present-design-of-thio-101-trial-at-european-society-for-medical-oncology-esmo-congress-2022\\\/\",\"name\":\"MAIA Biotechnology to Present Design of THIO-101 Trial at European Society for Medical Oncology (ESMO) Congress 2022 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2022-09-06T12:01:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maia-biotechnology-to-present-design-of-thio-101-trial-at-european-society-for-medical-oncology-esmo-congress-2022\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maia-biotechnology-to-present-design-of-thio-101-trial-at-european-society-for-medical-oncology-esmo-congress-2022\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/maia-biotechnology-to-present-design-of-thio-101-trial-at-european-society-for-medical-oncology-esmo-congress-2022\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MAIA Biotechnology to Present Design of THIO-101 Trial at European Society for Medical Oncology (ESMO) Congress 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MAIA Biotechnology to Present Design of THIO-101 Trial at European Society for Medical Oncology (ESMO) Congress 2022 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/maia-biotechnology-to-present-design-of-thio-101-trial-at-european-society-for-medical-oncology-esmo-congress-2022\/","og_locale":"en_US","og_type":"article","og_title":"MAIA Biotechnology to Present Design of THIO-101 Trial at European Society for Medical Oncology (ESMO) Congress 2022 - Pharma Trend","og_description":"Multicenter, open-label, dose-finding trial evaluating THIO sequenced with cemiplimab in patients with advanced non-small cell lung cancer CHICAGO&#8211;(BUSINESS WIRE)&#8211;MAIA Biotechnology, Inc. (NYSE American: MAIA) (\u201cMAIA,\u201d \u201cthe Company\u201d), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it will present the design of its ongoing THIO-101 trial at the European Society for Medical ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/maia-biotechnology-to-present-design-of-thio-101-trial-at-european-society-for-medical-oncology-esmo-congress-2022\/","og_site_name":"Pharma Trend","article_published_time":"2022-09-06T12:01:42+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/maia-biotechnology-to-present-design-of-thio-101-trial-at-european-society-for-medical-oncology-esmo-congress-2022\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/maia-biotechnology-to-present-design-of-thio-101-trial-at-european-society-for-medical-oncology-esmo-congress-2022\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"MAIA Biotechnology to Present Design of THIO-101 Trial at European Society for Medical Oncology (ESMO) Congress 2022","datePublished":"2022-09-06T12:01:42+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/maia-biotechnology-to-present-design-of-thio-101-trial-at-european-society-for-medical-oncology-esmo-congress-2022\/"},"wordCount":547,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/maia-biotechnology-to-present-design-of-thio-101-trial-at-european-society-for-medical-oncology-esmo-congress-2022\/","url":"https:\/\/pharma-trend.com\/en\/maia-biotechnology-to-present-design-of-thio-101-trial-at-european-society-for-medical-oncology-esmo-congress-2022\/","name":"MAIA Biotechnology to Present Design of THIO-101 Trial at European Society for Medical Oncology (ESMO) Congress 2022 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2022-09-06T12:01:42+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/maia-biotechnology-to-present-design-of-thio-101-trial-at-european-society-for-medical-oncology-esmo-congress-2022\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/maia-biotechnology-to-present-design-of-thio-101-trial-at-european-society-for-medical-oncology-esmo-congress-2022\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/maia-biotechnology-to-present-design-of-thio-101-trial-at-european-society-for-medical-oncology-esmo-congress-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"MAIA Biotechnology to Present Design of THIO-101 Trial at European Society for Medical Oncology (ESMO) Congress 2022"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47998","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=47998"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/47998\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=47998"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=47998"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=47998"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}